Further dissection of these mechanisms, for instance by perturbing CCT4 in vivo, will be critical to determine whether targeting this chaperonin can reverse Th2-dominated immune escape and reinvigorate anti-tumor immunity in LUAD. This evidence concerns the gene CCT4 and neoplasm.